首页> 美国卫生研究院文献>Integrated Pharmacy Research Practice >Chemotherapy e-prescribing: opportunities and challenges
【2h】

Chemotherapy e-prescribing: opportunities and challenges

机译:化疗电子处方:机遇与挑战

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chemotherapy drugs are characterized by low therapeutic indices and significant toxicities at clinically prescribed doses, raising serious issues of drug safety. The safety of the chemotherapy medication use process is further challenged by regimen complexity and need to tailor treatment to patient status. Errors that occur during chemotherapy prescribing are associated with serious and life-threatening outcomes. Computerized provider order entry (CPOE) systems were shown to reduce overall medication errors in ambulatory and inpatient settings. The adoption of chemotherapy CPOE is lagging due to financial cost and cultural and technological challenges. Institutions that adopted infusional or oral chemotherapy electronic prescribing modified existing CPOE systems to allow chemotherapy prescribing, implemented chemotherapy-specific CPOE systems, or developed home-grown chemotherapy electronic prescribing programs. Implementation of chemotherapy electronic prescribing was associated with a significant reduction in the risk of prescribing errors, most significantly dose calculation and adjustment errors. In certain cases, implementation of chemotherapy CPOE was shown to improve the chemotherapy use process. The implementation of chemotherapy CPOE may increase the risk of new types of errors, especially if processes are not redesigned and adapted to CPOE. Organizations aiming to implement chemotherapy CPOE should pursue a multidisciplinary approach engaging all stakeholders to guide system selection and implementation. Following implementation, organizations should develop and use a risk assessment process to identify and evaluate unanticipated consequences and CPOE-generated errors. The results of these analyses should serve to further enhance the chemotherapy electronic prescribing process and improve the quality and safety of cancer care.
机译:化学治疗药物的特点是在临床规定剂量下具有较低的治疗指数和明显的毒性,从而引发了严重的药物安全性问题。化疗药物使用过程的安全性进一步受到方案复杂性的挑战,并且需要根据患者状况调整治疗方案。化疗处方期间发生的错误与严重且威胁生命的结果相关。显示了计算机化的提供者订单输入(CPOE)系统可以减少门诊和住院患者的总体用药错误。由于财务成本以及文化和技术挑战,化学疗法CPOE的采用滞后。采用输液或口服化学电子处方的机构修改了现有的CPOE系统,以允许进行化学处方,实施了特定于化学疗法的CPOE系统,或者制定了自主研发的化学电子处方方案。实施化学药品电子处方可显着降低处方错误风险,尤其是剂量计算和调整错误的风险。在某些情况下,化疗CPOE的实施可改善化疗的使用过程。实施化学疗法CPOE可能会增加发生新类型错误的风险,尤其是如果流程没有经过重新设计并适应CPOE的话。旨在实施化学疗法CPOE的组织应采用多学科方法,邀请所有利益相关者参与,以指导系统的选择和实施。实施之后,组织应开发并使用风险评估流程来识别和评估意外后果和CPOE产生的错误。这些分析的结果应有助于进一步增强化学疗法的电子处方过程,并提高癌症护理的质量和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号